These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27438319)

  • 21. [PEGASUS - Ticagrelor in secondary prevention on patients after a myocardial infarction].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Jun; 61(6):511-5. PubMed ID: 26258965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
    Magnani G; Ardissino D; Im K; Budaj A; Storey RF; Steg PG; Bhatt DL; Cohen M; Oude Ophius T; Goudev A; Parkhomenko A; Kamensky G; Angiolillo DJ; López-Sendón J; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
    J Am Heart Assoc; 2021 Feb; 10(4):e017008. PubMed ID: 33559485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.
    Bonaca MP; Lesén E; Giannitsis E; Hedberg J; Jernberg T; Lambrelli D; Duong M; Maggioni AP; Ariza-Solé A; Ten Berg J; Storey RF
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):701-708. PubMed ID: 37653447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
    BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
    Easton JD; Aunes M; Albers GW; Amarenco P; Bokelund-Singh S; Denison H; Evans SR; Held P; Jahreskog M; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
    Circulation; 2017 Sep; 136(10):907-916. PubMed ID: 28655834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
    Storey RF; Angiolillo DJ; Bonaca MP; Thomas MR; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Mar; 67(10):1145-1154. PubMed ID: 26965534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
    Johnston SC; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KS;
    N Engl J Med; 2016 Jul; 375(1):35-43. PubMed ID: 27160892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
    Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
    Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience.
    Bergmeijer TO; Janssen PWA; van Oevelen M; van Rooijen D; Godschalk TC; Kelder JC; Deneer VHM; Serebruany VL; Ten Berg JM
    Cardiology; 2017; 138(3):164-168. PubMed ID: 28697492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?
    Serebruany V; Tomek A
    Int J Cardiol; 2016 Jul; 215():214-6. PubMed ID: 27128533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
    Capodanno D; Capranzano P; Buccheri S; Tamburino C
    Int J Cardiol; 2015 Dec; 201():276-8. PubMed ID: 26301657
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy.
    Amico F; Schlesinger A; Mazzoni J
    Postgrad Med; 2016; 128(2):164-9. PubMed ID: 26689345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
    de Waha A; Sandner S; von Scheidt M; Boening A; Koch-Buettner K; Hammel D; Hambrecht R; Danner BC; Schöndube FA; Goerlach G; Fischlein T; Schmoeckel M; Oberhoffer M; Schulz R; Walther T; Ziegelhöffer T; Knosalla C; Schönrath F; Beyersdorf F; Siepe M; Attmann T; Misfeld M; Mohr FW; Sievers HH; Joost A; Putman LM; Laufer G; Hamm C; Zeymer U; Kastrati A; Radke PW; Lange R; Cremer J; Schunkert H
    Am Heart J; 2016 Sep; 179():69-76. PubMed ID: 27595681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.
    Ariotti S; Gargiulo G; Valgimigli M
    Curr Cardiol Rep; 2017 Jan; 19(1):2. PubMed ID: 28097533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.
    Bonaca MP; Wiviott SD; Morrow DA; Steg PG; Hamm C; Bhatt DL; Storey RF; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Diaz R; Van de Werf F; Corbalán R; Goudev A; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Heart Assoc; 2018 Nov; 7(22):e009260. PubMed ID: 30571502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
    Serebruany VL
    Int J Cardiol; 2015 Dec; 201():508-12. PubMed ID: 26318512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.